In contrast, there were no significant phenotypic differences between the expanded (TCR-Vβ+) and residual (TCR-Vβ−) CD8+ T-cell populations in dasatinib-treated CML patients (Fig. 3A, bottom panel). Here, CD8A is linked to chronic myelogenous leukemia, BCR-ABL1 positive.